Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma

摘要

Context: Targeted agents, including the multitargeted receptor tyrosine kinase inhibitor sunitinib, have demonstrated clinical efficacy in the first- and second-line treatment of patients with metastatic renal cell carcinoma (mRCC). These agents have dramatically improved the outlook for such patients. However, treatment with targeted agents is associated with a distinct pattern of adverse events (AE) that must be effectively managed for patients to derive maximum possible benefit. Objective: To review the AEs observed in sunitinib studies as well as practical therapy-management strategies to maximize clinical benefit with targeted agents in mRCC.